FDA to release new guidance soon, clarifying its regulatory framework related to vaccines, particularly COVID-19 shots. Read ...

WASHINGTON — FDA Commissioner Martin Makary offered more details into the agency’s recently announced plans to place ...

Dr Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said: “This approval provides healthcare professionals with an innovative treatment option for [these ...

For the patient demanding access to the latest medicine or the healthcare professional desperate to be able to use a new advance in treatment, every extra day, week or month waiting counts.

As the incidence of cancer rises around the world, the demand for faster, more precise diagnoses is also on the rise. This demand will only intensify over time, as the worldwide incidence of ...

"We are taking these difficult, but necessary, actions as we restructure 23andMe and focus on the long-term success of our core consumer business and research partnerships," said Wojcicki.

Each programme includes undisclosed upfront and milestone payments plus royalties on sales, with Merck indicating in a statement that it will be funding the research. It’s the first major ...

GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, will get a rapid six-month review from the FDA when it is filed for approval, said the drugmaker this morning. The fast ...

AstraZeneca's oral therapy Truqap will soon be available for people with advanced breast cancer via the NHS in England – as long as testing is available to identify eligible patients. AKT ...

Delivery by drone is often talked about in the retail sector – to make delivery of consumer goods quicker and with greater convenience. However, Ben Hargreaves finds that the advantages for ...

Last year, AstraZeneca reported that a new drug to treat Wilson disease developed by its Alexion rare diseases unit had hit the mark in a phase 3 trial, setting it on course for regulatory filings.

The management of Israeli pharma group Teva has laid out its strategy for a return to growth after a challenging few years, with a greater emphasis on innovative medicines and a focus on complex ...